Achieve Life Sciences Inc Total Liabilities
Achieve Life Sciences Inc total liabilities. Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) has total liabilities worth $22.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ACHV financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Achieve Life Sciences Inc (1994–2025)
Total liabilities of Achieve Life Sciences Inc from 1994 to 2025. This chart illustrates how Achieve Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Achieve Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Achieve Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dodla Dairy Limited
NSE:DODLA
|
India | Rs4.01 Billion |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
China | CN¥9.84 Billion |
|
Ramkhamhaeng Hospital Public Company Limited
BK:RAM
|
Thailand | ฿22.65 Billion |
|
Fuda Alloy Materials Co Ltd
SHG:603045
|
China | CN¥2.47 Billion |
|
Hangzhou Huawang New Material Technology Co.Ltd.
SHG:605377
|
China | CN¥1.97 Billion |
|
BlackRock Utility & Infrastructure Trust
NYSE:BUI
|
USA | $805.10K |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
Taiwan | NT$3.45 Billion |
|
President Bakery Public Company Limited
BK:PB
|
Thailand | ฿1.13 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Achieve Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Achieve Life Sciences Inc's balance sheet.
Liquidity & Leverage Metrics
Achieve Life Sciences Inc Total Liabilities Ratios Explained
Achieve Life Sciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Achieve Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Achieve Life Sciences Inc (1994–2025)
The table below shows the annual total liabilities of Achieve Life Sciences Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.27 Million | +14.31% |
| 2024-12-31 | $17.73 Million | -14.82% |
| 2023-12-31 | $20.82 Million | -3.92% |
| 2022-12-31 | $21.67 Million | +11.27% |
| 2021-12-31 | $19.47 Million | +546.55% |
| 2020-12-31 | $3.01 Million | -0.53% |
| 2019-12-31 | $3.03 Million | -7.74% |
| 2018-12-31 | $3.28 Million | +63.04% |
| 2017-12-31 | $2.01 Million | -76.33% |
| 2016-12-31 | $8.50 Million | -59.05% |
| 2015-12-31 | $20.77 Million | -6.58% |
| 2014-12-31 | $22.23 Million | +20.32% |
| 2013-12-31 | $18.48 Million | +16.88% |
| 2012-12-31 | $15.81 Million | -57.42% |
| 2011-12-31 | $37.12 Million | -18.93% |
| 2010-12-31 | $45.79 Million | -0.50% |
| 2009-12-31 | $46.02 Million | +1027.14% |
| 2008-12-31 | $4.08 Million | -69.40% |
| 2007-12-31 | $13.34 Million | -47.57% |
| 2006-12-31 | $25.45 Million | +12.37% |
| 2005-12-31 | $22.65 Million | +548.37% |
| 2004-12-31 | $3.49 Million | +61.84% |
| 2003-12-31 | $2.16 Million | -2.34% |
| 2002-12-31 | $2.21 Million | +84.42% |
| 2001-12-31 | $1.20 Million | -79.34% |
| 2000-12-31 | $5.80 Million | -28.39% |
| 1999-12-31 | $8.10 Million | -28.32% |
| 1998-12-31 | $11.30 Million | +8.65% |
| 1997-12-31 | $10.40 Million | +4.00% |
| 1996-12-31 | $10.00 Million | +14.94% |
| 1995-12-31 | $8.70 Million | -28.69% |
| 1994-12-31 | $12.20 Million | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more